Abstract
Cell-to-cell transmission and subsequent amplification of pathological proteins promote neurodegenerative disease progression. Most research on this has focused on pathological protein seeds, but how their normal counterparts, which are converted to pathological forms during transmission, regulate transmission is less understood. Here we show in cultured cells that phosphorylation of soluble, nonpathological α-synuclein (α-Syn) at previously identified sites dramatically affects the amplification of pathological α-Syn, which underlies Parkinsonʼs disease and other α-synucleinopathies, in a conformation- and phosphorylation site-specific manner. We performed LC–MS/MS analyses on soluble α-Syn purified from Parkinsonʼs disease and other α-synucleinopathies, identifying many new α-Syn post-translational modifications (PTMs). In addition to phosphorylation, acetylation of soluble α-Syn also modified pathological α-Syn transmission in a site- and conformation-specific manner. Moreover, phosphorylation of soluble α-Syn could modulate the seeding properties of pathological α-Syn. Our study represents the first systematic analysis how of soluble α-Syn PTMs affect the spreading and amplification of pathological α-Syn, which may affect disease progression.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Peptide identification was performed in MaxQuant (1.6.1.0) using human reference database from Uniprot (reviewed canonical and isoforms; downloaded on 1 January 2018) and the search results were exported into Scaffold 4 (Proteome Software). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE37 partner repository with the dataset identifier PXD037994. Figure 3 and Supplementary Tables 4–8 are associated with LC–MS/MS data. Source data are provided with this paper.
Change history
09 October 2023
A Correction to this paper has been published: https://doi.org/10.1038/s41593-023-01474-6
References
Lippa, C. F. et al. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365–1370 (1998).
Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
Tu, P. H. et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415–422 (1998).
Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012).
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 14, 504–506 (2008).
Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008).
Braak, H. & Tredici, K. D. Neuroanatomy and pathology of sporadic Parkinson’s disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119 (2009).
Jucker, M. & Walker, L. C. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 21, 1341–1349 (2018).
Guo, J. L. & Lee, V. M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130–138 (2014).
Barrett, P. J. & Timothy Greenamyre, J. Post-translational modification of α-synuclein in Parkinsonʼs disease. Brain Res. 1628, 247–253 (2015).
Schmid, A. W., Fauvet, B., Moniatte, M. & Lashuel, H. A. α-Synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell. Proteom. 12, 3543–3558 (2013).
Burai, R., Ait-Bouziad, N., Chiki, A. & Lashuel, H. A. Elucidating the role of site-specific nitration of α-synuclein in the pathogenesis of Parkinsonʼs disease via protein semisynthesis and mutagenesis. J. Am. Chem. Soc. 137, 5041–5052 (2015).
Dikiy, I. et al. Semisynthetic and in vitro phosphorylation of α-synuclein at Y39 promotes functional partly helical membrane-bound states resembling those induced by PD mutations. ACS Chem. Biol. 11, 2428–2437 (2016).
Hejjaoui, M. et al. Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125. J. Am. Chem. Soc. 134, 5196–5210 (2012).
Levine, P. M. et al. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson’s disease. Proc. Natl Acad. Sci. USA 116, 1511–1519 (2019).
Mahul-Mellier, A. L. et al. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinsonʼs disease. Hum. Mol. Genet. 23, 2858–2879 (2014).
Oueslati, A., Schneider, B. L., Aebischer, P. & Lashuel, H. A. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl Acad. Sci. USA 110, E3945–E3954 (2013).
Paleologou, K. E. et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30, 3184–3198 (2010).
Negro, A., Brunati, A. M., Donella-Deana, A., Massimino, M. L. & Pinna, L. A. Multiple phosphorylation of α-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16, 210–212 (2002).
Chen, L. et al. Tyrosine and serine phosphorylation of α-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Investig. 119, 3257–3265 (2009).
Marotta, N. P. et al. α-Synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. Acta Neuropathol. Commun. 9, 188 (2021).
Schweighauser, M. et al. Structures of α-synuclein filaments from multiple system atrophy. Nature 585, 464–469 (2020).
Peng, C. et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 557, 558–563 (2018).
Pan, B., Rhoades, E. & Petersson, E. J. Chemoenzymatic semisynthesis of phosphorylated α-synuclein enables identification of a bidirectional effect on fibril formation. ACS Chem. Biol. 15, 640–645 (2020).
Pan, B. et al. Effects of glutamate arginylation on α-synuclein: studying an unusual post-translational modification through semisynthesis. J. Am. Chem. Soc. 142, 21786–21798 (2020).
Oueslati, A., Paleologou, K. E., Schneider, B. L., Aebischer, P. & Lashuel, H. A. Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson’s disease. J. Neurosci. 32, 1536–1544 (2012).
Brahmachari, S. et al. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J. Clin. Investig. 126, 2970–2988 (2016).
de Oliveira, R. M. et al. The mechanism of sirtuin 2-mediated exacerbation of α-synuclein toxicity in models of Parkinsonʼs disease. PLoS Biol. 15, e2000374 (2017).
Vicente Miranda, H. et al. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain 140, 1399–1419 (2017).
Marotta, N. P. et al. O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson’s disease. Nat. Chem. 7, 913–920 (2015).
Wang, J. et al. Protein arginylation targets α-synuclein, facilitates normal brain health and prevents neurodegeneration. Sci. Rep. 7, 11323 (2017).
Zhao, J. et al. α-Synuclein arginylation in the human brain. Transl. Neurodegener. 11, 20 (2022).
Morris, M. et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183–1189 (2015).
Narasimhan, S. et al. Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J. Neurosci. 37, 11406–11423 (2017).
Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011).
Luk, K. C. et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051–20056 (2009).
Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidence. Nucleic Acids Res. 50, D543–D552 (2022).
Acknowledgements
We thank Quantitative Proteomics Resource Core of School of Medicine at the University of Pennsylvania and Proteomics Core at Children’s Hospital of Philadelphia (CHOP) for performing the LC–MS/MS analysis. We thank S. Seeholzer, L. Spruce, H. Ding, H. Fazelinia and H. Lee (from CHOP) for helping with LC–MS/MS experiments. We thank D. Riddle for providing primary neurons, L. Romero for helping with quantification and all the other members of the Center for Neurodegenerative Disease Research for their support. We thank Lucy Ruoxi Shi for helping with the cartoon illustration of this work. This work was supported by NIH/NINDS Udall Center under grant NS53488 (to V.M.-Y.L.), NIA under grant U19 AG062418 (Center on Alpha-Synuclein Strains in Alzheimerʼs Disease and Related Dementias) (to V.M.-Y.L.), NIH/NINDS R01-NS103873 to E.J.P. (to V.M.-Y.L.), NIH/NINDS R01-NS128964 (to C.P.), CurePSP grant 672-2020-12 (to C.P.), the Ofer Nimerovsky Family Fund (to V.M.-Y.L.), the Jeff and Anne Keefer Fund (to V.M.-Y.L.) and the MSA Coalition Seed Grant (to C.P. and V.M.-Y.L.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author information
Authors and Affiliations
Contributions
C.P., V.L., S.Z. and R.Z. conceived experiments. C.P., S.Z. and R.Z. performed most of the experiments. B.P. and E.J.P. generate pY39 and pS87 α-synuclein monomer. H.X., M.F.O., R.J.G., J.Z., W.X. and E.M.K. performed cell culture experiments. L.Z. and H.A.L. performed biochemical experiments. S.-J.K. generated PFF. C.K.W., S.M. and H.V. identified and prepared human brain tissue for the preparation of pathological α-synuclein. X.C., C.Y. and B.A.G. performed LC–MS/MS experiments. Y.L. analyzed the data. C.P., J.Q.T., V.M.-Y.L., E.J.P. and H.A.L. wrote the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Neuroscience thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Figs. 1–13, Supplementary Tables 1–10 and Supplementary data files.
Source data
Source Data Fig. 1
Uncropped blots.
Source Data Fig. 1
Raw data.
Source Data Fig. 2
Uncropped blots.
Source Data Fig. 2
Raw data.
Source Data Fig. 4
Uncropped blots.
Source Data Fig. 4
Raw data.
Source Data Fig. 5
Raw data.
Source Data Fig. 6
Raw data.
Source Data Fig. 7
Raw data.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhang, S., Zhu, R., Pan, B. et al. Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein. Nat Neurosci 26, 213–225 (2023). https://doi.org/10.1038/s41593-022-01239-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41593-022-01239-7
This article is cited by
-
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease
npj Parkinson's Disease (2024)
-
Phosphorylation and O-GlcNAcylation at the same α-synuclein site generate distinct fibril structures
Nature Communications (2024)
-
Dopaminergic neuron loss in mice due to increased levels of wild-type human α-Synuclein only takes place under conditions of accelerated aging
Scientific Reports (2024)
-
Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia
Acta Neuropathologica (2024)
-
Current trends in basic research on Parkinson’s disease: from mitochondria, lysosome to α-synuclein
Journal of Neural Transmission (2024)